Abstract
Tumor cell arrest and tumor migration are two of the critical steps in the metastatic cascade. We hypothesized that these steps may be facilitated by the low density lipoprotein (LDL)-induced activation of microvessel endothelial cells (MVEC). The purpose of our study was to investigate the biological effects of an LDL-enriched milieu and the effects of the anticholesterol drug Lovastatin on metastatic behavior. The SW480 and SW620 are primary and metastatic human colonic adenocarcinoma cell lines derived from the same patient. We investigated the effect of LDL on adhesion and migration of the two tumor cell lines across human brain, lung, liver and dermal endothelial monolayers. Adhesion and migration assays were done before and after pretreat-ment of the MVEC or tumor cells with LDL (100 mg/ml) for 24 h. Although metastatic SW620 cells were more adherent to MVEC compared with primary SW480 cells, LDL pretreatment of SW480 and SW620 cells did not affect tumor cell adhesion to MVEC. In contrast, tumor cell migration was significantly increased across endothelial monolayers when MVEC were pretreated with LDL. Transendothelial cell migration was not sig-nificantly affected by pretreatment of the tumor cells with LDL. Lovastatin is an inhibitor of HMG-CoA reduc-tase, the rate-limiting enzyme in cholesterol biosynthesis. It has been shown to have anti-tumor activity in vitro. We investigated the effect of Lovastatin on tumor cell kinetics and tumor cell migration across MVEC. Growth curves and migration assays were done before and after pretreatment of the tumor cells with Lovastatin (30 mg/ml). Migration assays were also done after treatment of unstimulated or LDL-stimulated MVEC (100 mg/ml) for 24 h with Lovastatin. Lovastatin inhibited the in vitro growth of the metastatic SW620 cell line to a greater extent than the invasive SW480E cell line. On the other hand, pretreatment of tumor cells with Lovastatin (30 mg/ml) did not suppress transendothelial tumor cell migration of tumor cells. Finally, Lovastatin given to mice effectively suppressed the number of MCA-26 tumor colonies in the liver of Balb/c mice com-pared with untreated mice. ©Lippincott Williams & Wilkins
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Fidler IJ, 1990, Critical factors in the biology of human cancer metastasis: twenty-eighth Clowes Memorial Award Lecture. Cancer Res, 50, 6130-8.
Mehta N, Hordines J, Volpe C, Doerr R and Cohen SA, 1997, Cellular effects of hyper-cholesterolemia in modulation of cancer growth and metastasis: a review of the evidence. Surg. Oncol, 7, 179-86.
Cohen SA, Mahl T, Montesanti D, Hassett M and Barbera-Guillem E, 1995, Capacity of nonparenchymal liver cells to control metastasis. In Bouwens L, ed. NK Cells in the Liver. Austin, Landes Co. pp. 71-100.
Holland JA, Pritchard KA and Rogers NJ, 1993, Stemerman M.B: Perturbation of cultured endothelial cells by atherogenic levels of low density lipoprotein. Am J Pathol, 132, 474-8.
Lafrenie R, Shaughnessy SG and Orr FW, 1992, Cancer cell interactions with injured or activated endothelium. Cancer Mets Rev, 11, 377-88.
Alberts AW, Chen J and Kuron G, 1980, Mevinolin: a highly potent competitive inhibitor of HMG-CoA reductase and a cholesterol lowering agent. Proc Natl Acad Sci, 77,3957-61.
Sumi B, Beauchamp RD and Townsend CM, 1992, Inhibition of pancreatic adenocarcinoma cell growth by lovastatin. Gastroenterology, 103,982-9.
Vincent TS, Wulfert E and Merler E, 1991, Inhibition of growth factor signaling pathways by lovastatin. Biochem Biophys, Res Commun, 180, 1284-9.
Gebhardi A and Niendorf A, 1995, Effects of prevastatin, a hydroxymethyl glutaryl-CoA reductase inhibitor, on two human tumor cell lines. J Can Res Clin Oncol, 121, 343-9.
Barbera-Guillem E, Alonso-Varona A and Vidal-Vanachlocha F, 1989, Selective implantation and growth of liver metastasis in acinar zone one. Cancer Res, 49, 4003-10.
Schackert G, Price JE, Bucana CD and Fidler IJ, 1989, Unique patterns of brain metastasis produced by different human carcinomas in athymic nude mice. Int J Cancer, 44, 892-7.
Auerbach R et al, 1987, Specificity of adhesion between murine tumor cells and capillary endothelium: an in vitrocorrelate of preferential metastasis in vivo. Cancer Res, 47, 1492-6.
Pauli B et al., 1990, Organ preference of metastasis: the role of endothelial cell adhesion molecules. Cancer Mets Rev, 9, 175-89.
McCarthy SA, Kuzu I, Gatter KC and Bicknell R, 1991, Heterogeneity of the endothelial cell and its role in organ preference of tumor metastasis. TIBS, 12,462-7.
Danforth DN and Sgagias MK, 1993, Interleukin-1 alpha and interleukin-6 act additively to inhibit growth of MCF-7 breast cancer cells in vitro. Cancer Res, 53, 1538-45.
Reed MJ, Topping L, Coldham NG, Purohit A, Ghilchik MW and James VH, 1993, Control of aromatase activity in breast cancer cells: the role of cytokines and growth factors. J Steroid Biochem Mol Biol, 44, 589-96.
Cruse JP, Lewin MR and Clark CJ, 1982, Dietary cholesterol deprivation improves survival and reduces the incidence of metastatic colon cancer in dimethylhydrazide treated rats. Gut, 23, 594-9.
Kort WJ, Hulsmann WC and Stehman TE, 1989, Modulation of metastatic ability by inhibition of cholesterol synthesis. Clin Exp Metastasis, 7, 517-23.
Henriksen T, Evensen SA and Carlander B, 1979, Injury to human endothelial cells in culture induced by low density lipoproteins. Scand J Clin Lab Invest,39, 361-8.
Okada M, Sugita O, Miida T, Matsuto T and Inano K, 1995, Effects of modified low density lipoprotein and hypoxia on the expression of endothelial leukocyte adhesion molecule-1. Presse Medicale, 24, 483-8.
Morgan J, Smith JA, Wikins GM and Leake DS, 1993, Oxidation of low density lipoprotein by bovine and porcine aortic endothelial cells and porcine endocardial cells in culture. Atherosclerosis, 102, 209-16.
Murakami M, Ushio Y, Mihara Y, Kuratsu J, Horiuchi S and Morino Y, 1990, Cholesterol uptake by human glioma cells via receptor mediated endocytosis of low density lipoprotein. J Neurosurg, 73, 760-7.
Chambers AF, MacDonald IC, Schmidt EE, et al.,1995, Steps in tumor metastases: new concepts from intravidal videomicroscopy. Cancer Met Rev, 14, 279-301.
Pritchard KA, Grozek L, Smalley DM, et al., 1995, Native low-density lipoprotein increases endothelial nitric oxide synthetase generation of super oxide anion. Circulation Res, 77, 510-8.
Vitols S, 1991, Uptake of low density lipoprotein by malignant cells -possible therapeutic applications (Review). Cancer Cells, 3, 488-95.
Miller AC and Samid D, 1995, Tumor resistance to oxidative stress: association with ras oncogene expression and reversal by lovastatin, an inhibitor of p21ras isoprenylation. Int J Cancer, 60, 249-54.
Khan SG, Saxena R, Bickers DR, Mukhtar H and Agarwal R, 1995, Inhibition of ras p21 membrane localization and modulation of protein kinase C isozyme expression during regression of chemical carcinogen-induced murine skin tumors by lovastatin. Molec Carcino, 12, 205-12.
Jones KD, Couldwell WJ, Hinton DR, et al.,1991, Lovastatin induces growth inhibition and apoptosis in malignant human glioma cells. Biochem Biophys Res Commun 205, 1671-81.
Miller AC, Kariko K, Myers CE, Clark EP and Samid D, 1993, Increased radioresistance of EJ ras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21 ras isoprenylation. Int J Cancer, 53, 302-7.
Jani JP, Specht S, Stemmler N, et al., 1993, Metastasis B16F10 mouse melanoma inhibited by lovastatin, an inhibitor of cholesterol biosynthesis. Invasion and Metastasis, 13, 314-24.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mehta, N., Hordines, J., Sykes, D. et al. Low density lipoproteins and Lovastatin modulate the organ-specific transendothelial migration of primary and metastatic human colon adenocarcinoma cell lines in vitro. Clin Exp Metastasis 16, 587–594 (1998). https://doi.org/10.1023/A:1006548902592
Issue Date:
DOI: https://doi.org/10.1023/A:1006548902592